CEO Hanna Sjöström presented GPX Medical at Life Science Day in Gothenburg March 4th to 140 Swedish life science investors.

GPX Medical has set the foundation for commercialization of a new unique medical device for lung monitoring of preterm born infants with great potential on the Global market for neonatal care. The market potential is substantial, one out of ten infants are born preterm.

GPX Medical’s medical device, Neola, targets preterm born infants with respiratory problems. The company has had promising results from three studies with 32 newborns.

-We are planning for a CE-marked Neola in 2023, says Hanna Sjöström. The company has a parallell process with FDA to be able to sell in the U.S.

About GPX Medical

GPX Medical AB is revolutionizing neonatal intensive care with NEOLA®, a medical device that can offer continuous lung monitoring and real-time alerts of life-threatening complications using a cutting-edge technology that measures lung volume changes and oxygen gas concentration. NEOLA® has the potential to provide better care, fewer days in intensive care and healthier lives for preterm born infants. Founded in 2016 and headquartered in Lund, Sweden, GPX Medical is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to global health care.

For investors

Please contact CEO Hanna Sjöström for investment opportunities:
hanna.sjostrom@gpxmedical.se

Contact

GPX Medical AB
Tellusgatan 13
224 57 Lund
Sweden
info@gpxmedical.se

Organization number: 559069-9012